NEWS RELEASE, For Immediate Release

Andrew Gengos Joins PBS Biotech Advisory Board

Camarillo, California, February 23, 2012 – PBS Biotech®, Inc., the leading supplier of novel single-use bioreactors for the biopharmaceutical industry, announced today that Andrew Gengos, President and CEO of Neuraltus Pharmaceuticals,
has joined its Advisory Board.

“Andrew’s significant biopharmaceutical industry leadership, strategy and business development experience will be of tremendous value to PBS Biotech as we bring our innovative single-use bioreactor technology to market,” said Brian Lee, Ph.D., CEO and co-founder of PBS Biotech.

Mr. Gengos joined Neuraltus, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases, as CEO in February 2010. Prior to joining Neuraltus, Mr. Gengos spent more than seven years with Amgen where he was Vice President, Strategy and Corporate Development. He managed Amgen’s in-and-outbound business development activities, including acquisitions, licensing, spin outs, divestitures, corporate venture capital, and alliance management. Before joining Amgen, Mr. Gengos was Vice President, CFO, and CBO of Dynavax Technologies of Berkeley, California, where he was responsible for the company’s business functions including finance and accounting, fundraising, budgeting and planning, and business development. Mr. Gengos has been a Vice President of Strategy at the Chiron Corporation and a Senior Engagement Manager at McKinsey & Company.

“I am delighted to join PBS Biotech’s advisory board. The company has a real opportunity to meaningfully improve biological drug manufacturing processes with its enabling technology,” Gengos said.

Mr. Gengos was awarded his MBA from the Anderson School of Business at UCLA and received his BS degree in Chemical Engineering from MIT.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that designs and manufactures fully scalable and easy to use single-use bioreactors used by global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA., PBS Biotech www.pbsbiotech.com is a member of the BioProcess Systems Alliance (BPSA).

Contact:
PBS Biotech, Inc.
Lourie Zak, +1-805-482-7272
Chief Financial Officer

NEWS RELEASE, For Immediate Release

Robert F. Baltera, Jr. Joins PBS Biotech Advisory Board

Camarillo, California, January 30, 2012 – PBS Biotech®, Inc., the leading supplier of novel single-use bioreactors for the biopharmaceutical industry, announced today that Robert F. Baltera, Jr., former CEO of Amira Pharmaceuticals, has joined its Advisory Board.

“Bob is a seasoned executive with a wealth of experience from the biopharmaceutical industry that will strongly benefit PBS Biotech as we bring our innovative single-use bioreactor technology to the market,” said Brian Lee, Ph.D., CEO and co-founder of PBS Biotech.

Baltera was the CEO of Amira Pharmaceuticals from July 2007 to September 2011 when the company was sold to Bristol-Myers Squibb for $325 million and an additional $150 million in earn-out milestones. At Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases, Baltera was instrumental in focusing product development efforts, building its pipeline, leading efforts to establish key collaborations with partners such as GlaxoSmithKline, and successfully managing the sale of the company.

Prior to his role at Amira, Baltera acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. At Amgen, Baltera held a number of senior management positions, including his last role as vice president of corporate and contract manufacturing. A scientist by training, Baltera joined Amgen at the beginning of his career as a research associate, and quickly moved to the operations side of the business, working in finance, product development and commercial operations.

“I look forward to helping the PBS Biotech team advance their enabling technology in single-use bioreactors which has a strong opportunity to influence broad adoption in the industry” Baltera said.

Baltera has a master’s of business administration from the Anderson School at UCLA. He earned his bachelor’s degree in microbiology and a master’s degree in genetics from The Pennsylvania State University.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that designs and manufactures fully scalable and easy to use single-use bioreactors used by global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA., PBS Biotech www.pbsbiotech.com is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

NEWS RELEASE, For Immediate Release

George J. Morrow Joins PBS Biotech Advisory Board

Camarillo, California, January 9, 2012 – PBS Biotech®, Inc., the leading supplier of novel single-use bioreactors for the biopharmaceutical industry, announced today that George J. Morrow, former Executive Vice President, Global Commercial Operations, Amgen Inc, joined its Advisory Board.

“We’re honored to have Mr. Morrow as a member of our Advisory Board,” said Brian Lee, Ph.D., President and Chief Executive Officer, PBS Biotech. “With over 30 years of global commercial business operations experience at top biopharmaceutical firms, George has a broad and distinguished record of success. At this critical stage as we transition to a fully commercialized company, we look forward to benefiting from his expertise in the biotech industry,” he said.

“PBS Biotech has developed a novel, single-use bioreactor architecture and product set that holds a great potential to be the game changer for future bio-manufacturing by offering competitive advantage and sustained value. I am looking forward to contributing to the company’s rapid growth, industry adoption and operational success,” Morrow said.

Mr. Morrow served as Executive Vice President, Global Commercial Operations of Amgen Inc. from 2003 until 2011, overseeing all Amgen’s commercial activities in over 50 countries during a period of rapid growth with multiple product launches into competitive markets. From 2001 to 2003, he served as Executive Vice President, Worldwide Sales and Marketing. Prior to Amgen, Mr. Morrow had over 20 years of commercial experience at Merck and GlaxoWellcome Inc.

He served as President and Chief Executive Officer of GlaxoWellcome Inc. and as Managing Director of GlaxoWellcome U.K., both subsidiaries of GlaxoSmithKline plc. He was Group Vice President for Commercial Operations, Glaxo Inc. from 1993-1996.

Mr. Morrow holds a B.S. in chemistry from Southampton College, Long Island University; an M.S. in biochemistry from Bryn Mawr College; and an M.B.A. from Duke University’s Fuqua School of Business. He is a member of the Duke University Fuqua School of Business Advisory Board and Medical Center Board of Visitors. He is also a member of the Board of Directors of Align Technology, a global medical device company, and Human Genome Sciences (NASDAQ: HGSI) a biopharmaceutical firm. Mr. Morrow has served previously on boards for GlaxoWellcome Inc. and Johns Hopkins School of Public Health.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that designs and manufactures fully scalable and easy to use single-use bioreactors used by global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA., PBS Biotech www.pbsbiotech.com is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

NEWS RELEASE, For Immediate Release

Lourie Zak, former Amgen finance executive, joins PBS Biotech, Inc. as Chief Financial Officer

Zak brings wealth of biopharmaceutical, financial management and business expertise to fast growth biotech equipment firm

Camarillo, California, September 7, 2011–PBS Biotech®, Inc., the leading supplier of innovative single-use bioreactors for the fast growing biotechnology market, announced today Lourie Zak, a former executive director of finance at Amgen, has joined the company as Chief Financial Officer.

”Lourie is a great addition to the PBS Biotech executive team and will be a driver in managing our financial controls, providing financial leadership and decision support, and in securing capital for our growth,” said Dr. Brian Lee, president and co-founder of the company. “Her strong background in finance as well as knowledge of the biotech industry bring tremendous business depth and leadership experience that complements our team,” he said.

For the past eight years, Zak held executive roles of increasing responsibility at biotech leader Amgen. Joining Amgen in 2003, she served as special projects lead on the process improvements team overseeing the finance integration of Tularik a research firm acquired by Amgen and served for three years as European Controller based in Breda, The Netherlands for Amgen Europe. In that post she implemented the European Union controllership function, led efforts to establish a shared service center, and improved internal controls, financial reporting and compliance processes.

For the past four years, Zak was executive director finance for Amgen’s Global Commercial Operations at the Thousand Oaks, CA headquarters. She provided financial analysis and decision support to executive leadership in a rapidly changing environment that included product launches, global regulatory and reimbursement volatility, the enactment of U.S. healthcare reform and increased competition.

Prior to Amgen, Zak held controllership and vice president finance positions at various firms including Dream Works SKG, eToys, and Sony Pictures Television International. She began her career in tax with KPMG Peat Marwick and later Ernst & Young and served as director of tax and later director of financial reporting at Orion Pictures.

Zak takes over the financial reins at PBS Biotech as the company brings its novel single-use bioreactors to market. Rapid adoption of single-use bioreactors is occurring across all stages of the bioprocess as global biopharma firms embrace single-use technology to drive out costs in both R&D and production while increasing process flexibility, operational efficiency and accelerating time to market.

PBS Biotech offers a product line of bioreactors with the industry’s most advanced features such as ease of use, full scalability from lab to production, low shear by novel Air Wheel™ mixing mechanism and plug and play configurations. The bioreactors are used in developing and producing animal, insect, and plant cell cultures for creation of life saving and quality of life improving vaccines and therapeutic protein drugs including biosimilars. PBS was recently named Business of the Year by the Pacific Coast Business Times and in late August acquired Integrity CMI of Camarillo.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. PBS Biotech www.pbsbiotech.com
is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

PDF Version

NEWS RELEASE, For Immediate Release

PBS Biotech, Inc. Acquires Medical Devices
Contract Manufacturing Firm Integrity CMI

Fast growth biotech firm acquires full-service medical device manufacturer with ISO 13485 certification and FDA registration.

Camarillo, California, August 23, 2011–PBS Biotech®, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has acquired Integrity CMI, a Camarillo, CA based medical device design and manufacturing company. Under terms of the agreement PBS Biotech purchased Integrity CMI and will integrate the company into ongoing operations.

Integrity CMI has extensive experience in design, assembly, testing, packaging and sterilization of medical devices and biotech products. The company has certified class 7 (10,000) clean room operations as well as non-clean room assembly and testing facilities. The added technical capabilities and factory space will significantly augment PBS Biotech’s manufacturing capability for disposable vessels, bags, and related plastic parts assemblies of single-use bioreactors under stringent clean room environmental controls.

“Integrity CMI is a powerful addition to the company adding substantial ISO and FDA certified design, manufacturing and test capabilities,” said Dr. Brian Lee, co-founder and CEO of PBS Biotech. “Oscar Garza and his team are experts at medical and biotech equipment production and have extensive engineering and manufacturing experience vital to the rapid growth of PBS,” he said.

“We are thrilled to become part of the PBS team and to contribute to making the industry’s leading single-use bioreactor products,” said Mr. Garza, the CEO of Integrity and a 25-year engineering and manufacturing veteran of medical and pharma firms including Baxter, Bristol-Myers Squibb, and Medtronic. “PBS Biotech is an exciting company on a path to become a industry leader providing biopharma with innovative bioreactors that can dramatically improve the development of drugs and vaccines and reduce costs. We are pleased to be part of the family and to help the company to its next level of success,” he said.

Over the coming weeks the two companies, located in facilities just a few miles apart, will reconfigure the assets and personnel to maximize design and engineering operations and build out the manufacturing facilities, which hold ISO 13485 certification and are FDA registered. The facility will focus on manufacturing the PBS disposable vessels and bags employing the industry’s highest quality levels and standards. This will allow PBS Biotech to internally control and document every step of the production process from raw materials, assembly, final test, packaging, and sterilization to insure product quality and traceability.

Rapid adoption of single-use bioreactors is occurring across all stages of the bioprocess as firms embrace single-use technology to drive out costs in both R&D and production while increasing process flexibility, operational efficiency and accelerating time to market. PBS Biotech offers a product line of bioreactors with the industry’s most advanced features such as ease of use, full scalability from lab to production, low shear by novel Air Wheel™ mixing mechanism and plug and play configurations. The bioreactors are used in developing and producing animal, insect, and plant cell cultures for creation of life saving and quality of life improving therapeutic protein drugs and vaccines.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. PBS Biotech is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

www.pbsbiotech.com

PDF Version

NEWS RELEASE, For Immediate Release

PBS Biotech Named Business of the Year by Pacific Coast Business Times

PBS honored for developing advanced single-use bioreactors for biopharmas to produce vaccines, drugs and biosimilars for global market

Business of Year Award for West Ventura County was presented to Dr. Brian Lee, second from left, president of PBS Biotech, Inc. by Henry Dubroff, editor and chairman of Pacific Coast Business Times, far left. Congratulating Dr. Lee were US Rep. Lois Capps, CA-23, second from right, and Elizabeth Eckhols, far right, Regional Administrator, US Small Business Administration.

Dr. Brian Lee, co-founder and CEO of PBS Biotech, received the award for Business of the Year for West Ventura County, from editor and chairman Henry Dubroff during an awards ceremony held today at the Fess Parker’s Double Tree Resort, Santa Barbara. Pacific Coast Business Times is a weekly business newspaper covering the tri-counties of Ventura, Santa Barbara and San Luis Obispo.

“This is a tremendous honor for the PBS Biotech team to be recognized by Pacific Coast Business Times and the business community for our hard work and creativity in developing bioreactors that can accelerate the development of drugs and vaccines worldwide,” said Dr. Lee. “Our focus is to provide our biopharma customers with bioreactors and bioprocess solutions that deliver value and competitive advantage to their business,” he said.

PBS Biotech, which has corporate headquarters here, and includes sales, marketing, engineering, manufacturing and clean room operations, won over more than 70 firms nominated in its category. The company expects to make significant additions to its work force across all sectors over the coming months. The firm is growing rapidly as biopharma firms worldwide adopt single-use bioreactors, which offer lower capital and operating costs, increased manufacturing flexibility and shorten development time to market for drug and vaccine products.

The awards lunch was attended by over 150 local and regional business and government officials including US Rep. Lois Capps, CA-23; Brian Miller representing US Rep. Elton Gallegly, CA-24; Elizabeth Echols, Regional Administrator of the US Small

Business Administration and Bruce Stenslie, EDC-VC president & CEO. Keynote speaker was Linda Weinman, co-founder of lynda.com.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. PBS Biotech is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

www.pbsbiotech.com

PDF Version

Ventura County’s volatile job market

Another major employer leaves area, but job market shows signs of life

By Shane Cohn 10/27/

The headlines are fickle, at best. Unemployment is down this month, up last month; the economy is rising, diving, sustaining. But statistics don’t help pay the bills, they just help reporters fill stories and put politicians in office or back on the streets from whence they came.

Trends, on the other hand, are far more tangible. Beginning this past summer, the trend of major Ventura County companies leaving the state and laying off scores of employees in their wake – or significantly reducing their work forces as in the case of Amgen laying off 226 people this past week — has been a black mark for city governments and gut wrenching for those laid off.

It began in June, when Affinity Group, a major employer in the city of Ventura, put its headquarters up for sale, which also equated to massive employee layoffs. According to figures provided by Chief Executive Officer Marcus Lemonis, more than half the workforce was dismissed from the Ventura location. Approximately 70 employees will remain in the accounting, directories and rallies and events departments. The other functions of the company were moved or reassigned to the offices in Denver, Minneapolis and Bowling Green, Ky., according to Lemonis, who declined to comment any further. The former Affinity site off of Vista Del Mar Avenue is now in escrow with Somera Capital Management, a Santa Barbara-based boutique real estate investment firm, according to Nick Gregg, office and industrial specialist with CB Richard Ellis. Gregg, who marketed the building, said the asking price was $9.7 million, but couldn’t disclose the contract price until the deal closes. The site includes a 72,000-square-foot office building on 9.3 acres.

The Affinity Group departure marks the biggest corporation to leave Ventura since Kinko’s moved its corporate headquarters to Texas in 2002.

“You can blame Sacramento, but this is a costly part of the country to do business in,” said Ventura City Manager Rick Cole. “We are not in position to give the kind of incentives that a place in rural Mississippi or suburban Kentucky or Nevada can offer, because of state laws.”

In late August, 186 employees at SolarWorld Industries America in Camarillo were laid off. The largest domestic producer of solar panels announced it would be shifting production to its new facility in Hillsboro, Ore. The sales and marketing functions of the company would remain in Camarillo, about 114 employees.

“Still waiting for the smoke to clear,” said John Fraser, city of Camarillo’s senior management analyst. “It was terrible news for us and worse news for people being laid off.”

But as Camarillo awaited clear skies, two more major employers stormed out of town. Vitesse Semiconductor issued pink slips on Oct. 3 and announced it would shutter one of its Camarillo facilities. The company laid off 10 percent of its 467 employees, though its headquarters will still remain in Camarillo. Channel Microwave, which started in

Camarillo 25 years ago, is going to lay off 36 of its 50 employees and the manufacturing sector is being transferred to Tampa, according to Camarillo’s Sept. 30 Economic Development Report.

All is far from being lost, however, in the economic tides. Fraser said the city is on the verge of welcoming a company that will bring 300 jobs, but could not comment further on the deal. Camarillo is also host to emerging green and biotech businesses like carbon-fuel producer Cool Planet BioFuels and PBS Biotech, creating lines of disposable bioreactors, which began as a startup from a $250,000 loan from the Economic Development Collaborative-Ventura County. The company now has 20 employees.

In Ventura, the strategy, according to Cole, is “to make it easy on existing Ventura businesses to grow and expand, and for entrepreneurs to launch companies.” In January 2010, the city launched an “incubator” to foster and attract high-tech companies to the city. The incubator now houses 17 startups, according to Cole.

“Not all are going to grow up and become Microsoft,” he said. “But these weren’t in existence before we started.” One of the companies in the incubator, The Trade Desk, an online advertising ad exchange, now boasts 15 employees.

NEWS RELEASE, For Immediate Release

PBS Biotech Selects Green Cross Medical Sciences
as Exclusive Bioreactor Distributor in Korea

Firm’s single-use bioreactors offer enabling technology for Korean biopharmas to produce drugs, vaccines and biosimilars for global market

Camarillo, California, July 26, 2011–PBS Biotech, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has signed an exclusive distribution agreement in Korea with Green Cross Medical Sciences Corp. (GCMS), a division of Green Cross Corporation one of Korea’s largest pharmaceutical firms. Under terms of the agreement GCMS will market, sell and support the complete line of PBS Biotech single-use bioreactors for R&D and production to the more than 200 biopharma firms of the burgeoning Korean drug, vaccine and biosimilar industry.

The Korean biopharma industry, now ranked the 12th largest in the world and 4th largest in Asia, has announced plans to be a major global supplier within the next two decades. Today, the country’s pharmaceutical revenues top $20 billion with 8% coming from biotech.

“With the PBS Biotech family of bioreactors, GCMS is expanding the use of disposable bioreactors in the industry,” said Mr. Seung-Sam Seo, president of GCMS. “We believe the PBS single-use bioreactor systems, which offer tremendous value and benefits to our customers, will be a significant and cost effective contributor in helping the industry meet the drug and vaccine needs of our own population and for international customers,” he said.

“GCMS is a premier medical products sales and marketing organization well positioned to introduce and advance the application of our next generation bioreactor systems in the Korea market,” said Dr. Brian Lee, president and co-founder of PBS Biotech.

Rapid adoption of single-use bioreactors is occurring across all stages of the bioprocess as firms embrace single-use technology to drive out costs in both R&D and production while increasing process flexibility, operational efficiency and accelerating time to market. PBS Biotech bioreactors, which employ a low shear Air Wheel™ mixing mechanism, are used in developing plant, animal and insect cell cultures in lab, clinical, seed train and production uses. The bioreactors work with popular industry probes, sensors and analytic devices and perfusion systems including Refine Technology.

Single-use means they use disposable plastic media vessels or bags to grow cell cultures. Unlike the large and complex conventional stainless steel and glass bioreactor systems, which are expensive to buy and operate and require extensive cleaning using massive amounts of water and other utilities, the disposable or single-use bioreactor vessel or bag is used one time and discarded. The industry is rapidly moving to single-use not only to save cost and accelerate time to market but also to promote a ‘green biopharma environment’ and more sustainable operations.

“Our single-use bioreactors are the products of choice for any size biopharma firm migrating from costly and fragmented legacy lab to production bioreactor equipment to a single-use solution providing unequalled mixing performance, low profile and ease of use,” stated James B. Schultz, PBS Biotech vice president of sales and marketing. “With PBS and its channel partners we help create, deliver and measure specific value for our customers resulting in distinct competitive advantage for their business,” he said.

The PBS bioreactors are the industry’s only systems providing low shear mixing to cells and full scalability from R&D to production. The company offers a full line of single-use bioreactors ranging from 3-liter bench-top units to 80-liter stand-alone systems and will be announcing larger scale units in the months ahead. All disposable bags and systems use industry leading USP Class VI materials.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. PBS Biotech is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

www.pbsbiotech.com

PDF Version

NEWS RELEASE, For Immediate Release

PBS Biotech Exhibits at ESACT, Selected to Present Technical Poster to Entire Global Group of Scientists

Poster highlighting novel mixing mechanism and characterization using the PBS single-use bioreactor Air-Wheel™ system wins accolades from ESACT judges

Camarillo, California, May 31, 2011–PBS Biotech, Inc., a developer of state of the art single-use bioreactors used in the fast growing biotechnology market, announced today its technical poster was selected for presentation before the entire 22^nd Annual European Society for Animal Cell Technology (ESACT) conference in Vienna, Austria, May 15 – 18. The conference, which brings together leading biotech and pharmaceutical scientists from companies, academic institutions and research centers from around the world to share scientific gains and equipment, is the premier biotech exhibition in Europe.

The poster, a winner in its category, outlines the scientific experiments the company has conducted recently using the Air-Wheel™ mixing technology in its single-use bioreactors with world leading academic institutions and biotech firms demonstrating rapid mixing, low shear and high cell density growth. The poster is entitled: “Characterization of Novel Pneumatic Mixing for Single-Use Bioreactor Application” and can be downloaded from the PBS Biotech web site by clicking here.

On the final day of ESACT, Dr. Brian Lee, PBS Biotech president and co-founder, presented the poster abstract and results before the full ESACT attendee list of nearly 1,000 world-renown scientists and researchers.

In its abstract PBS Biotech team and its collaboration partners outlined the company’s novel bioreactor system which incorporates the patented Air-Wheel technology, promotes uniform and homogeneous mixing and offers low shear environment for cell culture, as evidenced by mixing tests and computational fluid dynamics (CFD) modeling performed over a wide range of working volumes.

The poster was developed based on recent biological tests conducted with Keck Graduate Institute, Claremont, CA; Instituto de Biologia Experimental e Tecnologico (IBET), Lisbon, Portugal, and Green Cross Corporation, Korea. These tests and production runs have shown scalable growth performance for a high cell density process in 3 liter and 15 liter PBS systems and comparable growth and product performance in the 250 liter PBS system against a 300 liter stirred tank system using an Fc-fusion protein-producing process. The poster was jointly created with Dr. Matthew Croughan at KGI, Dr. Manual Carrondo of IBET Portugal, and Sang-Hoon Paik, of Green Cross Central Research Center, Seoul.

PBS bioreactor systems are the first with a pneumatic mixing device powered solely by gas buoyancy, eliminating the need for an external mechanical agitator. The patented design of the Air-Wheel mixing device promotes not only high tangential fluid flow around the wheel but also efficient radial and axial flow. The leverage effect of the Air- Wheel mixing device allows lower gassing requirement (v/v) with increasing working volume.

At ESACT the company exhibited its product line of next generation single-use bioreactors for use in developing cell cultures for wide range of products including mAbs, proteins, vaccines, viruses, stem cells and personalized medicine. The company displayed its PBS 3, PBS 15 and PBS 80 liter bioreactors used in batch, fed batch, perfusion and transient transfection processes and use with micro-carriers and many other cell culture apps.

The company projects rapid adoption of single-use bioreactors across all stages of the bioprocess as firms desire to embrace single-use technology in general and a biotech industry desiring to drive out costs in both R&D and production while increasing process flexibility, operational efficiency and accelerating time to market.

The PBS Biotech line of products are most advanced in the industry featuring ease of use, full scalability from lab to production, low shear from the novel Air-Wheel™ mixing mechanism and plug and play configurations.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies. The company is a member of the BioProcess Systems Alliance (BPSA).

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

www.pbsbiotech.com

PDF Version

NEWS RELEASE, For Immediate Release

Former Amgen executive Dr. Geoffrey Slaff joins
PBS Biotech, Inc. Scientific Advisory Board

Biotech industry expertise in process development, engineering and quality provides technical and quality leadership to the fast growing single-use bioreactor firm.

Camarillo, California, June 1, 2011–PBS Biotech, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today Dr. Geoffrey Slaff, recently retired Senior Vice President (SVP) of Process and Product Engineering at Amgen, Inc., the global biotechnology leader with over $15B in sales and 17,000 employees, has joined the firm’s Scientific Advisory Board (SAB). The SAB includes accomplished executives, business leaders, and scientists from the leading academic institutes and biopharmaceutical companies, and provides both technical and business expertise to the PBS Biotech team.

Dr. Slaff brings a wide range of expertise and experience to PBS Biotech from his 27 years in bioprocess development, product engineering, and quality in biotechnology industry. He also led the global quality operations at Amgen as SVP of Quality insuring Amgen’s production sites met corporate and regulatory requirements for the production of products used to treat patients suffering from cancer, kidney disease, bone disease and other serious illnesses.

PBS Biotech’s single-use bioreactors help reduce costs and accelerate time to market for worldwide manufacturers of biological drugs, vaccines and biosimilars. “Geoff is recognized as a leader and expert in quality and process throughout all stages of biopharmaceutical product development and manufacturing. He is a tremendous asset to the company by helping us reach the next level of success as our products are commercialized and adopted in the market,” said Dr. Brian Lee, president and co-founder of PBS Biotech.

“The adoption of single-use bioreactors is expected to grow dramatically in the next few years as the industry embraces the inherent benefits of this technology,’” said Dr. Slaff. “PBS Biotech has developed very interesting and innovative technology to deliver the next generation single-use bioreactors which can offer cost savings, process flexibility and production efficiency” he said.

Dr. Slaff earned a PhD in biochemical engineering from University of Pennsylvania and worked as Executive Director, Research and Development at Serono International and VP at Synergen prior to joining Amgen.

About PBS Biotech

PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented pneumatic mixing technology with intuitive user interface designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies.

Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177

www.pbsbiotech.com

PDF Version